HPV Vaccine Deal Gives GSK Royalties From Merck's Product
This article was originally published in The Pink Sheet Daily
Executive Summary
A cross-licensing deal between Merck and GlaxoSmithKline settles a dispute over several patents relating to separate Phase III human papilloma virus vaccines. Merck will make an upfront payment to GSK and pay royalties. MedImmune and Australia-based CSL may now receive payments from both companies.
You may also be interested in...
Gardasil Generated $10 Mil. In First 11 Days On The Market
Merck will pay royalties of between 24%-26% of worldwide sales of Gardasil in the aggregate, including payments to CSL Limited relating to technology used in the human papillomavirus vaccine
Gardasil Generated $10 Mil. In First 11 Days On The Market
Merck will pay royalties of between 24%-26% of worldwide sales of Gardasil in the aggregate, including payments to CSL Limited relating to technology used in the human papillomavirus vaccine
Merck Files ProQuad MMR/Varicella Combo Pediatric Vaccine
Company expects action on the BLA for a combination of its M-M-R II and Varivax vaccines by "early July" 2005. Three additional Merck vaccines are slated for submission over the next year, including agents for HPV and shingles.